Phase III Study with FOLFIRI + Cetuximab Versus FOLFIRI + Cetuximab Followed by Cetuximab Alone in <i>RAS</i> and <i>BRAF</i> WT mCRCCarmine Pinto, Evaristo Maiello, Emiliano Tamburini et al.|Future Oncology|2018Cited by 7
Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016).Angela Damato, Carmine Pinto, Domenico Bilancia et al.|Journal of Clinical Oncology|2024Cited by 1
RAS/BRAF testing of circulating cell-free DNA (cfDNA) in RAS/BRAF wild-type (RAS/BRAF <sup>WT</sup> ) metastatic colorectal cancer (mCRC) patients: Preliminary results of the phase III LIBImAb study.Anna Maria Rachiglio, Carmine Pinto, Angela Damato et al.|Journal of Clinical Oncology|2025Cited by 1